InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
66,785.55
(
0.10%
)
Post# of 3956
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

whytestocks

Send PM Follow Ignore
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

whytestocks

Re: None

Tuesday, 09/29/2020 5:45:32 PM

Tuesday, September 29, 2020 5:45:32 PM

Post# of 3956
Just In: $KLDO Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome Metabolic Therapy (MMT™) candidate KB295 in patients with mild-to-moderate ulcerative coliti...

Read the whole news KLDO - Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up